Judith G. Villablanca, MD

Title(s)Clinical Professor of Pediatrics (Part-Time)
SchoolKeck School of Medicine of Usc
AddressChildren's Hospital Los Angeles
Off Campus
Los Angeles CA 90027
Phone+1 323 361 5687
vCardDownload vCard

    Collapse Overview 

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Nat Med. 2023 05; 29(5):1092-1102. Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablanca JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada H, Ghazarian S, States L, Marshall L, Chesler L, Granger M, Desai AV, Mody R, Morgenstern DA, Shusterman S, Macy ME, Pinto N, Schleiermacher G, Vo K, Thurm HC, Chen J, Liyanage M, Peltz G, Matthay KK, Berko ER, Maris JM, Marachelian A, Mossé YP. PMID: 37012551; PMCID: PMC10202811.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    2. Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. Cancer. 2022 11 01; 128(21):3775-3783. Park JR, Villablanca JG, Hero B, Kushner BH, Wheatley K, Beiske KH, Ladenstein RL, Baruchel S, Macy ME, Moreno L, Seibel NL, Pearson AD, Matthay KK, Valteau-Couanet D. PMID: 36101004; PMCID: PMC9614386.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy. Pediatr Blood Cancer. 2022 09; 69(9):e29719. Asgharzadeh S, Marachelian A, Villablanca JG, Liu WY, Kennedy R, Sposto R, Naranjo A, Tenney S, Yu AL, Ozkaynak MF, Sondel PM, Park JR, Seeger RC. PMID: 35441784; PMCID: PMC9329214.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    4. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. J Clin Oncol. 2021 11 01; 39(31):3506-3514. DuBois SG, Granger MM, Groshen S, Tsao-Wei D, Ji L, Shamirian A, Czarnecki S, Goodarzian F, Berkovich R, Shimada H, Villablanca JG, Vo KT, Pinto N, Mosse YP, Maris JM, Shusterman S, Cohn SL, Goldsmith KC, Weiss B, Yanik GA, Twist CJ, Irwin MS, Haas-Kogan DA, Park JR, Marachelian A, Matthay KK. PMID: 34270348; PMCID: PMC8547934.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    5. A safety and feasibility trial of 131 I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study. Pediatr Blood Cancer. 2021 10; 68(10):e29117. Weiss BD, Yanik G, Naranjo A, Zhang FF, Fitzgerald W, Shulkin BL, Parisi MT, Russell H, Grupp S, Pater L, Mattei P, Mosse Y, Lai HA, Jarzembowski JA, Shimada H, Villablanca JG, Giller R, Bagatell R, Park JR, Matthay KK. PMID: 34028986; PMCID: PMC9150928.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    6. A single-arm study of systemic and sub-Tenon chemotherapy for Groups C and D intraocular retinoblastoma: A Children's Oncology Group study (ARET 0231). Pediatr Blood Cancer. 2020 09; 67(9):e28502. Jubran RF, Villablanca JG, Krailo M, Piao J, Huang L, Murphree AL, O'Brien J, Gombos D, Shields CL, Meadows A, Chintagumpala M. PMID: 32589362; PMCID: PMC7857974.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. Premature epiphyseal growth plate arrest after isotretinoin therapy for high-risk neuroblastoma: A case series and review of the literature. Pediatr Blood Cancer. 2020 08; 67(8):e28236. Duvalyan A, Cha A, Goodarzian F, Arkader A, Villablanca JG, Marachelian A. PMID: 32386124.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    8. Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. Pediatr Blood Cancer. 2019 07; 66(7):e27736. Braunstein SE, London WB, Kreissman SG, Villablanca JG, Davidoff AM, DeSantes K, Castleberry RP, Murray K, Diller L, Matthay K, Cohn SL, Shulkin B, von Allmen D, Parisi MT, Van Ryn C, Park JR, La Quaglia MP, Haas-Kogan DA. PMID: 30968542; PMCID: PMC7281832.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    9. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatr Blood Cancer. 2018 07; 65(7):e27023. Pinto N, DuBois SG, Marachelian A, Diede SJ, Taraseviciute A, Glade Bender JL, Tsao-Wei D, Groshen SG, Reid JM, Haas-Kogan DA, Reynolds CP, Kang MH, Irwin MS, Macy ME, Villablanca JG, Matthay KK, Park JR. PMID: 29603591; PMCID: PMC6040651.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    10. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma. Pediatr Blood Cancer. 2018 05; 65(5):e26940. Villablanca JG, Ji L, Shapira-Lewinson A, Marachelian A, Shimada H, Hawkins RA, Pampaloni M, Lai H, Goodarzian F, Sposto R, Park JR, Matthay KK. PMID: 29350464; PMCID: PMC7456604.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    11. Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Clin Cancer Res. 2017 Sep 15; 23(18):5374-5383. Marachelian A, Villablanca JG, Liu CW, Liu B, Goodarzian F, Lai HA, Shimada H, Tran HC, Parra JA, Gallego R, Bedrossian N, Young S, Czarnecki S, Kennedy R, Weiss BD, Goldsmith K, Granger M, Matthay KK, Groshen S, Asgharzadeh S, Sposto R, Seeger RC. PMID: 28559462.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    12. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017 Aug 01; 35(22):2580-2587. Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D. PMID: 28471719; PMCID: PMC5676955.
      View in: PubMed   Mentions: 114     Fields:    Translation:Humans
    13. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer. 2016 08; 63(8):1349-56. Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, Shimada H, Reynolds CP. PMID: 27092812; PMCID: PMC8992729.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCellsCTClinical Trials
    14. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG). Eur J Cancer. 2015 Nov; 51(16):2465-72. Zhou MJ, Doral MY, DuBois SG, Villablanca JG, Yanik GA, Matthay KK. PMID: 26254811; PMCID: PMC4607645.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    15. Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. Pediatr Blood Cancer. 2015 Oct; 62(10):1739-46. Anderson CP, Matthay KK, Perentesis JP, Neglia JP, Bailey HH, Villablanca JG, Groshen S, Hasenauer B, Maris JM, Seeger RC, Reynolds CP. PMID: 26153194.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    16. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15; 21(12):2715-21. DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen E, Giacomini K, Weiss B, Cohn SL, Granger MM, Yanik GA, Hawkins R, Courtier J, Jackson H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Villablanca JG, Marachelian A, Matthay KK. PMID: 25695691; PMCID: PMC4470833.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCellsCTClinical Trials
    17. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow Transplant. 2015 Apr; 21(4):673-81. Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Koga D, Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK. PMID: 25639769.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    18. Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study. BMC Res Notes. 2014 Apr 23; 7:256. Kang MH, Villablanca JG, Glade Bender JL, Matthay KK, Groshen S, Sposto R, Czarnecki S, Ames MM, Reynolds CP, Marachelian A, Maurer BJ. PMID: 24755475; PMCID: PMC4006848.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    19. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013 Sep; 14(10):999-1008. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG. PMID: 23890779; PMCID: PMC3963485.
      View in: PubMed   Mentions: 141     Fields:    Translation:HumansCTClinical Trials
    20. Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatr Blood Cancer. 2013 Nov; 60(11):1801-8. Maurer BJ, Kang MH, Villablanca JG, Janeba J, Groshen S, Matthay KK, Sondel PM, Maris JM, Jackson HA, Goodarzian F, Shimada H, Czarnecki S, Hasenauer B, Reynolds CP, Marachelian A. PMID: 23813912; PMCID: PMC4066886.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    21. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. J Nucl Med. 2013 Apr; 54(4):541-8. Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, Villablanca JG, Maris JM, Park JR, Cohn SL, McGrady P, Matthay KK. PMID: 23440556; PMCID: PMC5503147.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    22. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol. 2012 Oct 01; 30(28):3525-32. Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, Hadjidaniel M, Liu CW, Metelitsa LS, Pique-Regi R, Wakamatsu P, Villablanca JG, Kreissman SG, Matthay KK, Shimada H, London WB, Sposto R, Seeger RC. PMID: 22927533; PMCID: PMC3675667.
      View in: PubMed   Mentions: 157     Fields:    Translation:HumansCells
    23. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. J Nucl Med. 2012 Jul; 53(7):1155-63. Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, Shimada H, Barrett J, Lafrance N, Babich J. PMID: 22700000.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    24. The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma. Pediatr Blood Cancer. 2012 May; 58(5):675-81. Marachelian A, Shimada H, Sano H, Jackson H, Stein J, Sposto R, Matthay KK, Baker D, Villablanca JG. PMID: 22493777.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    25. Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clin Cancer Res. 2012 May 01; 18(9):2679-86. DuBois SG, Chesler L, Groshen S, Hawkins R, Goodarzian F, Shimada H, Yanik G, Tagen M, Stewart C, Mosse YP, Maris JM, Tsao-Wei D, Marachelian A, Villablanca JG, Matthay KK. PMID: 22421195; PMCID: PMC6814395.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    26. Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991-2010. Pediatr Blood Cancer. 2012 Jun; 58(6):905-9. Gozali AE, Britt B, Shane L, Gonzalez I, Gilles F, McComb JG, Krieger MD, Lavey RS, Shlien A, Villablanca JG, Erdreich-Epstein A, Dhall G, Jubran R, Tabori U, Malkin D, Finlay JL. PMID: 21990040.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    27. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin Cancer Res. 2011 Nov 01; 17(21):6858-66. Villablanca JG, London WB, Naranjo A, McGrady P, Ames MM, Reid JM, McGovern RM, Buhrow SA, Jackson H, Stranzinger E, Kitchen BJ, Sondel PM, Parisi MT, Shulkin B, Yanik GA, Cohn SL, Reynolds CP. PMID: 21908574; PMCID: PMC3207022.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    28. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol. 2011 Oct; 68(4):1057-65. Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, Groshen S, Hellriegel ET, Bensen-Kennedy D, Matthay KK, Brodeur GM, Maris JM. PMID: 21340605; PMCID: PMC4238911.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCellsCTClinical Trials
    29. A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer. 2011 Aug; 57(2):275-82. Russell HV, Groshen SG, Ara T, DeClerck YA, Hawkins R, Jackson HA, Daldrup-Link HE, Marachelian A, Skerjanec A, Park JR, Katzenstein H, Matthay KK, Blaney SM, Villablanca JG. PMID: 21671363; PMCID: PMC3117015.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    30. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010 Sep 30; 363(14):1324-34. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM, Children's Oncology Group. PMID: 20879881; PMCID: PMC3086629.
      View in: PubMed   Mentions: 767     Fields:    Translation:Humans
    31. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma. Pediatr Blood Cancer. 2011 Feb; 56(2):191-201. Quach A, Ji L, Mishra V, Sznewajs A, Veatch J, Huberty J, Franc B, Sposto R, Groshen S, Wei D, Fitzgerald P, Maris JM, Yanik G, Hawkins RA, Villablanca JG, Matthay KK. PMID: 20830775; PMCID: PMC3006009.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    32. Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation. Pediatr Blood Cancer. 2010 Jul 15; 55(1):42-6. Khatua S, Dhall G, O'Neil S, Jubran R, Villablanca JG, Marachelian A, Nastia A, Lavey R, Olch AJ, Gonzalez I, Gilles F, Nelson M, Panigrahy A, McComb G, Krieger M, Fan J, Sposto R, Finlay JL. PMID: 20222020.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    33. Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group. Pediatr Blood Cancer. 2010 Apr; 54(4):596-602. Bensimhon P, Villablanca JG, Sender LS, Matthay KK, Park JR, Seeger R, London WB, Yap JS, Kreissman SG. PMID: 20049927; PMCID: PMC2905158.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    34. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009 Nov 10; 27(32):5343-9. Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, Jackson HA, Mari Aparici C, Carlson D, Maris J, Hawkins R, Matthay KK. PMID: 19805691; PMCID: PMC2773221.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    35. Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol. 2009 Mar 01; 27(7):1020-5. Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM. PMID: 19171714; PMCID: PMC2738616.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    36. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J Clin Oncol. 2009 Mar 10; 27(8):1290-6. Wagner LM, Villablanca JG, Stewart CF, Crews KR, Groshen S, Reynolds CP, Park JR, Maris JM, Hawkins RA, Daldrup-Link HE, Jackson HA, Matthay KK. PMID: 19171709; PMCID: PMC2667827.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    37. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009 Mar 01; 27(7):1007-13. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG. PMID: 19171716; PMCID: PMC2738615.
      View in: PubMed   Mentions: 365     Fields:    Translation:Humans
    38. Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009 Jan; 52(1):44-50. Park JR, Villablanca JG, London WB, Gerbing RB, Haas-Kogan D, Adkins ES, Attiyeh EF, Maris JM, Seeger RC, Reynolds CP, Matthay KK, Children's Oncology Group. PMID: 18937318; PMCID: PMC2731719.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    39. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol. 2006 Jul 20; 24(21):3423-30. Children's Oncology Group (CCG 09709), Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP, Reynolds PC. PMID: 16849757.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    40. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol. 2006 Jan 20; 24(3):500-6. Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM. PMID: 16421427.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    41. A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas. Cancer. 2005 Nov 01; 104(9):1968-74. Packer RJ, Krailo M, Mehta M, Warren K, Allen J, Jakacki R, Villablanca JG, Chiba A, Reaman G. PMID: 16177987.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    42. Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas. Cancer. 2005 Sep 15; 104(6):1281-7. Packer RJ, Krailo M, Mehta M, Warren K, Allen J, Jakacki R, Villablanca JG, Chiba A, Reaman G. PMID: 16078267.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    43. Approaches to treatment for extraocular retinoblastoma: Children's Hospital Los Angeles experience. J Pediatr Hematol Oncol. 2004 Jan; 26(1):31-4. Jubran RF, Erdreich-Epstein A, Butturini A, Murphree AL, Villablanca JG. PMID: 14707710.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    44. Retinoid therapy of high-risk neuroblastoma. Cancer Lett. 2003 Jul 18; 197(1-2):185-92. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. PMID: 12880980.
      View in: PubMed   Mentions: 140     Fields:    Translation:Humans
    45. Successful multimodality therapy of recurrent multifocal juvenile granulosa cell tumor of the ovary. J Pediatr Hematol Oncol. 2002 Mar-Apr; 24(3):229-33. Erdreich-Epstein A, Monforte HL, Lavey RS, Joshi S, Phillips JD, Villablanca JG. PMID: 11990313.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    46. Long-term quality of life and neuropsychologic functioning for patients with CNS germ-cell tumors: from the First International CNS Germ-Cell Tumor Study. Neuro Oncol. 2001 07; 3(3):174-83. Sands SA, Kellie SJ, Davidow AL, Diez B, Villablanca J, Villablanca J, Weiner HL, Pietanza MC, Balmaceda C, Finlay JL. PMID: 11465398; PMCID: PMC1920620.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    47. Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors. Med Pediatr Oncol. 2000 Dec; 35(6):719-23. Park JR, Slattery J, Gooley T, Hawkins D, Lindsley K, Villablanca JG, Matthay KK, Sanders JE. PMID: 11107155.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    48. Surveillance imaging in children with medulloblastoma (posterior fossa PNET). Pediatr Radiol. 2000 Jul; 30(7):447-50. Roebuck DJ, Villablanca JG, Maher K, Nelson MD. PMID: 10929362.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    49. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J Neurosurg. 2000 Feb; 92(2):249-54. Packer RJ, Raffel C, Villablanca JG, Tonn JC, Burdach SE, Burger K, LaFond D, McComb JG, Cogen PH, Vezina G, Kapcala LP. PMID: 10659011.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    50. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999 Oct 14; 341(16):1165-73. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. PMID: 10519894.
      View in: PubMed   Mentions: 573     Fields:    Translation:HumansCTClinical Trials
    51. Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors. J Clin Oncol. 1998 Mar; 16(3):937-44. Ozkaynak MF, Matthay K, Cairo M, Harris RE, Feig S, Reynolds CP, Buckley J, Villablanca JG, Seeger RC. PMID: 9508176.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    52. A Phase I study of human gamma interferon gene-transduced tumor cells in patients with neuroblastoma. Hum Gene Ther. 1998 Feb 10; 9(3):379-90. Seeger RC, Rosenblatt JD, Duerst RE, Reynolds CP, Villablanca JG, Hasenauer B, Feig SA. PMID: 9508055.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    53. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol. 1996 Nov; 114(11):1348-56. Murphree AL, Villablanca JG, Deegan WF, Sato JK, Malogolowkin M, Fisher A, Parker R, Reed E, Gomer CJ. PMID: 8906025.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansAnimals
    54. Chemotherapy without irradiation--a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study. J Clin Oncol. 1996 Nov; 14(11):2908-15. Balmaceda C, Heller G, Rosenblum M, Diez B, Villablanca JG, Kellie S, Maher P, Vlamis V, Walker RW, Leibel S, Finlay JL. PMID: 8918487.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansCTClinical Trials
    55. Esthesioneuroblastoma in the pediatric age-group: the role of chemotherapy and autologous bone marrow transplantation. Int J Pediatr Otorhinolaryngol. 1996 Sep; 37(1):45-52. Nguyen QA, Villablanca JG, Siegel SE, Crockett DM. PMID: 8884406.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    56. Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation. Cancer Chemother Pharmacol. 1996; 39(1-2):34-41. Khan AA, Villablanca JG, Reynolds CP, Avramis VI. PMID: 8995497.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    57. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol. 1995 Apr; 13(4):894-901. Villablanca JG, Khan AA, Avramis VI, Seeger RC, Matthay KK, Ramsay NK, Reynolds CP. PMID: 7707116.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    58. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. Eur J Cancer. 1995; 31A(4):572-5. Matthay KK, O'Leary MC, Ramsay NK, Villablanca J, Reynolds CP, Atkinson JB, Haase GM, Stram DO, Seeger RC. PMID: 7576971.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    59. Bone abnormalities detected with skeletal scintigraphy after bone marrow harvest in patients with childhood neuroblastoma. Radiology. 1994 Sep; 192(3):755-8. Ortiz SS, Miller JH, Villablanca JG, Seeger RC. PMID: 8058943.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    60. Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum Gene Ther. 1994 Jul; 5(7):863-90. Raffel C, Culver K, Kohn D, Nelson M, Siegel S, Gillis F, Link CJ, Villablanca JG, Anderson WF. PMID: 7981311.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    61. Hypercalcemia: a dose-limiting toxicity associated with 13-cis-retinoic acid. Am J Pediatr Hematol Oncol. 1993 Nov; 15(4):410-5. Villablanca JG, Khan AA, Avramis VI, Reynolds CP. PMID: 8214363.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    62. Viridans streptococcal shock in bone marrow transplantation patients. Am J Hematol. 1993 Apr; 42(4):354-8. Steiner M, Villablanca J, Kersey J, Ramsay N, Haake R, Ferrieri P, Weisdorf D. PMID: 8493985.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    63. Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma. J Clin Oncol. 1993 Apr; 11(4):623-9. Campbell LA, Seeger RC, Harris RE, Villablanca JG, Matthay KK. PMID: 8478657.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    64. Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res. 1991; 366:527-33. Seeger RC, Villablanca JG, Matthay KK, Harris R, Moss TJ, Feig SA, Selch M, Ramsay N, Reynolds CP. PMID: 2068169.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    See more options in the Advanced Search tab

    Judith's Networks
    Concepts (254)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (29)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.